August 2012

The US Patent and Trademark Office (USPTO) has issued notices of allowance for two Mystic Pharmaceuticals patents related to its VersiDoser and VRx2 intranasal delivery platforms. The VersiDoser platform is used for packaging and aerosol… Read more . . .

Chiesi Farmaceutici will acquire all outstanding shares of Cornerstone Therapeutics for $9.50 per share, the companies have announced. Chiesi already owns almost 60% of Cornerstone outstanding common shares. Cornerstone announced in February 2013 that it… Read more . . .

Sigma-Tau PharmaSource and Aradigm have announced that Sigma-Tau PharmaSource will provide clinical and commercial manufacturing services for Aradigm’s Pulmaquin inhaled ciprofloxacin. Pulmaquin is in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis. Terms… Read more . . .

Activaero has announced that it will collaborate with Chiesi Farmaceutici on an inhaled treatment for cystic fibrosis that would deliver a Chiesi drug using Activaero’s FAVORITE (Flow And Volume Regulated Inhalation Technology) system. Financial details… Read more . . .

Civitas Therapeutics will use $38 million in new financing for continued development of its CVT-301 inhaled L-dopa through Phase 3 clinical trials, the company has announced. A Phase 2B study of the drug, which is… Read more . . .

The European Patent Office has granted a patent for the XCaps dry powder inhaler, Hovione has announced. The company filed for the patent in June 2011. Hovione VP Peter Villax, who co-invented the inhaler, commented,… Read more . . .

According to Insmed Incorporated both the US and European patent offices are granting new patents related to the company’s Arikace liposomal amikacin for inhalation to treat Pseudomonas aeruginosa lung infections in cystic fibrosis patients and… Read more . . .